ITeos Therapeutics Inc
ITOS
Company Profile
Business description
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Contact
321 Arsenal Street
WatertownMA02472
USAT: +1 339 217-0162
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
173
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.80 | 80.80 | 0.93% |
| CAC 40 | 7,537.57 | 52.09 | -0.69% |
| DAX 40 | 23,269.01 | 81.54 | -0.35% |
| Dow JONES (US) | 42,581.78 | 374.96 | 0.89% |
| FTSE 100 | 8,758.04 | 16.61 | -0.19% |
| HKSE | 24,127.03 | 437.90 | 1.85% |
| NASDAQ | 19,630.97 | 183.56 | 0.94% |
| Nikkei 225 | 38,769.12 | 415.03 | 1.08% |
| NZX 50 Index | 12,521.62 | 11.03 | -0.09% |
| S&P 500 | 6,025.17 | 57.33 | 0.96% |
| S&P/ASX 200 | 8,551.20 | 76.30 | 0.90% |
| SSE Composite Index | 3,411.39 | 29.81 | 0.88% |